粉样蛋白减少对认知变化的估计影响:在一系列先验中进行贝叶斯更新
Sarah F Ackley1, Jingxuan Wang2, Ruijia Chen1
1Department of Epidemiology, Boston University, Boston, Massachusetts, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 31, 2023
概括
最近针对粉样蛋白的药物试验表明,阿尔茨海默病患者的认知效益很小. 贝叶斯分析表明这种效应,但必须对风险和成本进行权衡.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物统计学 生物统计学
背景情况:
- 最近的临床试验 (CLARITY-AD,GRADUATE I/II,TRAILBLAZER-ALZ 2) 对阿尔茨海默病的粉素向疗法重新产生了兴趣.
- 在试验数据发布之前,关于粉样蛋白降低对认知功效的先前信念有显著的变化.
研究的目的:
- 用贝叶斯方法量化评估粉样蛋白减少对认知功能的影响.
- 根据新的临床试验数据,更新关于粉样蛋白向药物的疗效的先前信念.
主要方法:
- 使用了来自CLARITY-AD,GRADUATE I/II和TRAILBLAZER-ALZ 2试验的公开数据.
- 估计了粉样蛋白减少对临床痴呆症评分尺度,盒子总和 (CDR-SB) 评分的影响.
- 应用贝叶斯定理来更新一系列先前的信念与试验衍生的估计.
主要成果:
- 在结合了新的试验数据后,对于广泛的先前信念的可信间隔排除了"无效"情景.
- 贝叶斯分析表明,在各种起始假设中,粉样减少对CDR-SB得分的小但一致的好处.
结论:
- 理性观察者,鉴于试验数据,将推断出粉样蛋白减少疗法的适度认知益处.
- 这些药物的临床实用性需要平衡观察到的认知益处与它们的相关机会成本和潜在副作用.
更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.8K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
相关概念视频
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200